Skip to main content

A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention Deficit/Hyperactivity Disorder

Clinical Trial Grant
Duke Scholars

Administered By

Psychiatry & Behavioral Sciences

Awarded By

Shire Pharmaceutical Development US Inc.

Start Date

June 1, 2015

End Date

April 18, 2017
 

Administered By

Psychiatry & Behavioral Sciences

Awarded By

Shire Pharmaceutical Development US Inc.

Start Date

June 1, 2015

End Date

April 18, 2017